Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
Open accessAbstract
High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Conditional knockout mice, using the Cre-lox system for cell type specificity, have been used to reproduce oncogenic mutations and homologous recombination defects to study ovarian cancer development and responses to clinically relevant treatments such as platinum-based drugs and PARP inhibitors.
“Conditional knockout mice, using the Cre-lox system for cell type specificity, have been used to reproduce oncogenic mutations and HR defects to study ovarian cancer development and responses to clinically relevant treatments such as platin-based drugs and PARPis (Szabova et al., 2012; Perets et al., 2013; Szabova et al., 2014; Zhai et al., 2017).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Perets et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,459 · see citing works
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,179 · see citing works
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C. M., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,114 · see citing works
Jonkers, J., Meuwissen, R. L. J., van der Gulden, H. M. L., Peterse, H. L., van der Valk, M., & Berns, A. J. M. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053 · see citing works
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C. M., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 913 · see citing works
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M. R., Medeiros, F., Saleemuddin, A., Garber, J. E., Birch, C., Mou, H., Gordon, R., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 897 · see citing works
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829 · see citing works
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 786 · see citing works
Xu, X., Wagner, K., Larson, D. M., Ohler, Z. W., Li, C., Ried, T., Hennighausen, L. G., Wynshaw-Boris, A. J., & Deng, C. (1999) · Nature Genetics · doi:10.1038/8743 · Cited by 758 · see citing works
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D. G., & Jacks, T. (2004) · Nature Medicine · doi:10.1038/nm1173 · Cited by 601 · see citing works
Early restriction of peripheral and proximal cell lineages during formation of the lung
Perl, A. T., Wert, S. E., Nagy, A., Lobe, C. G., & Whitsett, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152238499 · Cited by 525 · see citing works
Gewinner, C. A., Wang, Z. C., Richardson, A. L., Teruya‐Feldstein, J., Etemadmoghadam, D., Bowtell, D. D. L., Barretina, J., Lin, W. M., Rameh, L. E., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 456 · see citing works
A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
Laury, A., Perets, R., Piao, H.-Y., Krane, J., Barletta, J., French, C., Chirieac, L., Lis, R., Loda, M., Hornick, J., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318216c112 · Cited by 429 · see citing works
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423 · see citing works
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412 · see citing works
Self-citationAre All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Przybycin, C. G., Kurman, R. J., Ronnett, B. M., Shih, I., & VANG, R. S. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ef7b16 · Cited by 410 · see citing works
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 400 · see citing works
Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene
Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Sun, H., Liu, X., & Wu, H. (2002) · genesis · doi:10.1002/gene.10036 · Cited by 387 · see citing works
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 356 · see citing works
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche
Flesken‐Nikitin, A., Hwang, C., Cheng, C.-Y., Michurina, T. V., Enikolopov, G., & Nikitin, A. Y. (2013) · Nature · doi:10.1038/nature11979 · Cited by 345 · see citing works
WU, R. T., Hendrix, N. D., Kuick, R. D., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 312 · see citing works
Traykova-Brauch, M., Schönig, K., Greiner, O., Miloud, T., Jauch, A., Bode, M., Felsher, D., Glick, A., Kwiatkowski, D., Bujard, H., et al. (2008) · Nature Medicine · doi:10.1038/nm.1865 · Cited by 297 · see citing works
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Leeper, K., Garcia, R., Swisher, E., Goff, B., Greer, B., & Paley, P. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6779 · Cited by 295 · see citing works
Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S. S., & Crum, C. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.012 · Cited by 292 · see citing works
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280 · see citing works
Self-citationFlesken‐Nikitin, A., Choi, K., Eng, J. P., Shmidt, E. N., & Nikitin, A. Y. (2003) · PubMed · Cited by 271 · see citing works
Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A., Richardson, J. E., & the Mouse Genome Database Group (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr974 · Cited by 243 · see citing works
Expression of PAX8 in Normal and Neoplastic Tissues
Tacha, D., Zhou, D., & Cheng, L. (2011) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182025f66 · Cited by 231 · see citing works
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Laury, A. R., Hornick, J. L., Perets, R., Krane, J. F., Corson, J. M., Drapkin, R., & Hirsch, M. S. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181da7687 · Cited by 229 · see citing works
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 215 · see citing works
Status of Tumor Markers in Ovarian Cancer Screening
Bast, R. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.068 · Cited by 205 · see citing works
Emerging roles for PAX8 in ovarian cancer and endosalpingeal development
Bowen, N. J., Logani, S., Dickerson, E. B., Kapa, L. B., Akhtar, M., Benigno, B. B., & McDonald, J. F. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.052 · Cited by 199 · see citing works
Veeck, J., Ropero, S., Setién, F., González‐Suárez, E., Osório, A., Benitez, J. J., Herman, J. G., & Esteller, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1010 · Cited by 173 · see citing works
Mittag, J., Winterhager, E., Bauer, K., & Grümmer, R. (2006) · Endocrinology · doi:10.1210/en.2006-1054 · Cited by 127 · see citing works
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 123 · see citing works
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122 · see citing works
Karst, A. M., Levanon, K., Duraisamy, S., Liu, J. F., Hirsch, M. S., Hecht, J. L., & Drapkin, R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.021 · Cited by 92 · see citing works
Distant metastases in ovarian cancer: association with p53 mutations.
Sood, A. K., Sorosky, J. I., Dolan, M., Anderson, B., & Buller, R. E. (1999) · PubMed · Cited by 84 · see citing works
Clark-Knowles, K. V., Garson, K., Jonkers, J., & Vanderhyden, B. C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.09.026 · Cited by 76 · see citing works
Mullany, L. K., Fan, H.-Y., Liu, Z., White, L. D., Marshall, A. N., Gunaratne, P. H., Anderson, M. L., Creighton, C. J., Xin, L., Deavers, M. T., et al. (2011) · Oncogene · doi:10.1038/onc.2011.70 · Cited by 73 · see citing works
Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma
Jazaeri, A. A., Bryant, J. L., Park, H., Li, H., Dahiya, N., Stoler, M. H., Ferriss, J. S., & Dutta, A. (2011) · Neoplasia · doi:10.1593/neo.11138 · Cited by 71 · see citing works
Clark-Knowles, K. V., Senterman, M. K., Collins, O. M., & Vanderhyden, B. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008534 · Cited by 61 · see citing works
Type I to Type II Ovarian Carcinoma Progression
WU, R. T., Baker, S. J., Hu, T. C., Norman, K. M., Fearon, E. R., & Cho, K. R. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.031 · Cited by 56 · see citing works
Phosphoinositide 3‐kinase and INPP4B in human breast cancer
Bertucci, M. C., & Mitchell, C. A. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12036 · Cited by 54 · see citing works
Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 45 · see citing works
Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions
Chene, G., Tchirkov, A., Eymard-Pierre, É., Dauplat, J., Raoelfils, I., Cayre, A., Watkin, E., Vago, P., & Penault-Llorca, F. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3947 · Cited by 42 · see citing works
Kuhn, E., Meeker, A. K., Visvanathan, K., Gross, A. L., Wang, T., Kurman, R. J., & Shih, I. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.67 · Cited by 35 · see citing works
The tubal hypothesis of ovarian cancer: caution needed
Collins, I. M., Domchek, S. M., Huntsman, D. D., & Mitchell, G. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70222-4 · Cited by 31 · see citing works
Flagged first, then by citations
3 of the 58 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,365 · see citing works
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362 · see citing works
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Narayanan, J., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,116 · see citing works
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 933 · see citing works
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi‐Galy, S. I., Papp, E., Hallberg, D. L., Niknafs, N., Adleff, V., Noë, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 762 · see citing works
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M. A., Fu, L., Goyeneche, A. A., Gao, Z., & Telleria, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 685 · see citing works
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts
Eckert, M. A., Coscia, F., Chryplewicz, A., Chang, J. W., Hernandez, K. M., Pan, S., Tienda, S. M., Nahotko, D. A., Li, G., Blaženović, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1173-8 · Cited by 507 · see citing works
The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids
Kessler, M., Hoffmann, K., Brinkmann, V., Thieck, O., Jackisch, S., Toelle, B., Berger, H., Mollenkopf, H., Mangler, M., Sehouli, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9989 · Cited by 466 · see citing works
Chandler, R. L., Damrauer, J. S., Raab, J. R., Schisler, J. C., Wilkerson, M. D., Didion, J. P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7118 · Cited by 320 · see citing works
Diagnosis and Treatment of Ovarian Cancer
Orr, B. C., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322 · see citing works
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P., & Drapkin, R. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 316 · see citing works
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.113 · Cited by 294 · see citing works
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L., Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00388-9 · Cited by 296 · see citing works
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M. K., Shih, I., Wang, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 290 · see citing works
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., von Strandmann, E. P., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 259 · see citing works
Prat, J., D′Angelo, E., & Espinosa, Í. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 277 · see citing works
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E. Y., Kim, O., Schilder, J. M., Coffey, D., Cho, C., & Bast, R. C. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 267 · see citing works
The Origin of Ovarian Cancer Species and Precancerous Landscape
Shih, I., Wang, Y., & Wang, T. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.09.006 · Cited by 255 · see citing works
Loret, N., Denys, H. G., Tummers, P., & Berx, G. (2019) · Cancers · doi:10.3390/cancers11060838 · Cited by 241 · see citing works
Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Wang, Y., Zhao, G., Condello, S., Huang, H., Cárdenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1488 · Cited by 244 · see citing works
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 232 · see citing works
Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A., & Neel, B. G. (2019) · Nature Communications · doi:10.1038/s41467-019-13116-2 · Cited by 235 · see citing works
Ducie, J. A., Dao, F., Considine, M., Olvera, N., Shaw, P. A., Kurman, R. J., Shih, I., Soslow, R. A., Cope, L., & Levine, D. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01217-9 · Cited by 225 · see citing works
Eckert, M. A., Pan, S., Hernandez, K. M., Loth, R. M., Andrade, J., Volchenboum, S. L., Faber, P. W., MONTAG, A. G., Lastra, R. R., Peter, M. E., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0607 · Cited by 216 · see citing works
Hu, Z., Artibani, M., Alsaadi, A., Wietek, N. C., Morotti, M., Shi, T., Zhong, Z., González, L. S., El-Sahhar, S., Carrami, E. M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.003 · Cited by 189 · see citing works
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 189 · see citing works
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 186 · see citing works
Lecker, L. S. M., Berlato, C., Maniati, E., Delaine-Smith, R., Pearce, O. M. T., Heath, O. M., Nichols, S. J., Trevisan, C., Novak, M., McDermott, J. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0536 · Cited by 158 · see citing works
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 149 · see citing works
Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer
Nayak, A. P., Kapur, A., Barroilhet, L. M., & Patankar, M. S. (2018) · Cancers · doi:10.3390/cancers10090337 · Cited by 146 · see citing works
Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer
Elias, K. M., Fendler, W. M., Stawiski, K., Fiascone, S. J., Vitonis, A. F., Berkowitz, R. S., Frendl, G., Konstantinopoulos, P. A., Crum, C. P., Kędzierska, M., et al. (2017) · eLife · doi:10.7554/elife.28932 · Cited by 143 · see citing works
Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention
Hanley, G. E., Pearce, C. L., Talhouk, A., Kwon, J. S., Finlayson, S. J., McAlpine, J. N., Huntsman, D. D., & Miller, D. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47343 · Cited by 137 · see citing works
Sherman‐Baust, C. A., Kuhn, E., Valle, B. L., Shih, I., Kurman, R. J., Wang, T., Amano, T., Ko, M. S. H., Miyoshi, I., Araki, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4353 · Cited by 136 · see citing works
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136 · see citing works
RNA sequencing (RNA-Seq) and its application in ovarian cancer
Wang, J., Dean, D. C., Hornicek, F. J., Huirong, S., & Duan, Z. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.002 · Cited by 134 · see citing works
Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 134 · see citing works
Suryawanshi, S., Huang, X., Elishaev, E., Budiu, R. A., Zhang, L., Kim, S., Donnellan, N. M., Mantia-Smaldone, G. M., Ma, T., Tseng, G. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1338 · Cited by 130 · see citing works
Wilson, M. R., Reske, J. J., Holladay, J., Moldovan, G. E., Rhodes, M., Koeman, J. M., Adams, M., Johnson, B. K., Su, R., Joshi, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11403-6 · Cited by 128 · see citing works
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 125 · see citing works
Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease
Clark, K. L., George, J. W., Przygrodzka, E., Plewes, M. R., Hua, G., Wang, C., & Davis, J. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac013 · Cited by 123 · see citing works
Lõhmussaar, K., Kopper, O., Korving, J., Begthel, H., Vreuls, C. P. H., van Es, J. H., & Clevers, H. C. (2020) · Nature Communications · doi:10.1038/s41467-020-16432-0 · Cited by 122 · see citing works
Sundar, S. S., Neal, R. D., & Kehoe, S. T. (2015) · BMJ · doi:10.1136/bmj.h4443 · Cited by 120 · see citing works
Screening for ovarian cancer: imaging challenges and opportunities for improvement
Mathieu, K. B., Bedi, D. G., Thrower, S. L., Qayyum, A., & Bast, R. C. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17557 · Cited by 118 · see citing works
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 117 · see citing works
It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research
Perets, R., & Drapkin, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1382 · Cited by 116 · see citing works
Functional neuronal circuits promote disease progression in cancer
Kovacs, A., Vermeer, D. W., Madeo, M., Reavis, H. D., Vermeer, S. J., Williamson, C. S., Rickel, A. P., Stamp, J., Lucido, C. T., Cain, J. T., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4443 · Cited by 119 · see citing works
Maniati, E., Berlato, C., Gopinathan, G., Heath, O. M., Kotantaki, P., Lakhani, A., McDermott, J. R., Pegrum, C., Delaine‐Smith, R. M., Pearce, O. M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.12.034 · Cited by 115 · see citing works
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111 · see citing works
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 112 · see citing works
Dinh, H. Q., Lin, X., Abbasi, F., Nameki, R. A., Haro, M., Olingy, C. E., Chang, H. S. Y., Hernández, L., Gayther, S. A., Wright, K. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108978 · Cited by 108 · see citing works
Walton, J. B., Farquharson, M., Mason, S. M., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D. J., Matzuk, M. M., Kim, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17119-1 · Cited by 110 · see citing works
Dorayappan, K. D. P., Gardner, M. L., Hisey, C. L., Zingarelli, R. A., Smith, B. Q., Lightfoot, M. D. S., Gogna, R., Flannery, M. M., Hays, J. L., Hansford, D. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3538 · Cited by 109 · see citing works
Martins, F. C., de Santiago, I., Trinh, A. C., Xian, J., Guo, A., Sayal, K., Jimenez‐Liñan, M., Deen, S., Driver, K. E., Mack, M. L., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0526-8 · Cited by 108 · see citing works
Genetic and molecular changes in ovarian cancer
Hollis, R. L., Hollis, R. L., Gourley, C., & Gourley, C. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0024 · Cited by 104 · see citing works
Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
von Strandmann, E. P., Reinartz, S., Wager, U., & Müller, R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.12.005 · Cited by 102 · see citing works
Mhawech-Fauceglia, P., Yan, L., Sharifian, M., Ren, X., Liu, S., Kim, G., Gayther, S. A., Pejovic, T., & Lawrenson, K. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0153-7 · Cited by 95 · see citing works
Dong, R., Liu, X., Zhang, Q., Jiang, Z., Li, Y., Wei, Y., Li, Y., Yang, Q., Liu, J., Wei, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2522 · Cited by 99 · see citing works
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
Liu, C., Barger, C. J., & Karpf, A. R. (2021) · Cancers · doi:10.3390/cancers13123065 · Cited by 97 · see citing works
Deciphering the BRCA1 Tumor Suppressor Network
Jiang, Q., & Greenberg, R. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.667931 · Cited by 95 · see citing works
High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease
Zhai, Y., WU, R. T., Kuick, R. D., Sessine, M. S., Schulman, S., Green, M., Fearon, E. R., & Cho, K. R. (2017) · The Journal of Pathology · doi:10.1002/path.4927 · Cited by 95 · see citing works
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
Nelson, L., Tighe, A., Golder, A., Littler, S., Bakker, B., Moralli, D., Baker, S. M., Donaldson, I. J., Spierings, D. C. J., Wardenaar, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14551-2 · Cited by 94 · see citing works
Scattolin, T., Bortolamiol, E., Visentin, F., Palazzolo, S., Caligiuri, I., Perin, T., Canzonieri, V., Demitri, N., Rizzolio, F., & Togni, A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002199 · Cited by 95 · see citing works
Organoids of the female reproductive tract
Chumduri, C., & Turco, M. Y. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02028-0 · Cited by 99 · see citing works
Serous tubal intraepithelial neoplasia: the concept and its application
Meserve, E. E. K., Brouwer, J., & Crum, C. P. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.238 · Cited by 94 · see citing works
MacFawn, I., Magnon, G. C., Gorecki, G., Kunning, S. R., Rashid, R., Ernest, M., Atiya, H. I., Ruffin, A. T., Taylor, S., Soong, T. R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.007 · Cited by 94 · see citing works
PRKCI promotes immune suppression in ovarian cancer
Sarkar, S., Bristow, C. A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S. Y., et al. (2017) · Genes & Development · doi:10.1101/gad.296640.117 · Cited by 93 · see citing works
Self-citationRahmanto, Y. S., Shen, W., Shi, X., Chen, X. X., Yu, Y., Yu, Z.-C., Miyamoto, T., Lee, M.-H., Singh, V., Asaka, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16416-0 · Cited by 93 · see citing works
Chlamydia infection depends on a functional MDM2-p53 axis
González, E., Rother, M., Kerr, M. C., Al‐Zeer, M. A., Lubad, M. A., Kessler, M., Brinkmann, V., Loewer, A., & Meyer, T. F. (2014) · Nature Communications · doi:10.1038/ncomms6201 · Cited by 93 · see citing works
Ghosh, A., Syed, S. M., & Tanwar, P. S. (2017) · Development · doi:10.1242/dev.149989 · Cited by 92 · see citing works
Zhang, S., Iyer, S., Ran, H., Dolgalev, I., Gu, S. S., Wei, W., Foster, C., Loomis, C. A., Olvera, N., Dao, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0455 · Cited by 88 · see citing works
Paffenholz, S. V., Salvagno, C., Ho, Y.-J., Limjoco, M., Baslan, T., Tian, S., Kulick, A. R., de Stanchina, E., Wilkinson, J. E., Barriga, F. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117754119 · Cited by 90 · see citing works
Ovary and fimbrial stem cells: biology, niche and cancer origins
Ng, A., & Barker, N. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4056 · Cited by 87 · see citing works
Huang, H.-S., Chu, S., Hsu, C., Chen, P., Ding, D., Chang, M.-Y., & Chu, T. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv132 · Cited by 89 · see citing works
Kuhn, E., Wang, T., Doberstein, K., Bahadirli-Talbott, A., Ayhan, A., Sehdev, A. E. S., Drapkin, R., Kurman, R. J., & Shih, I. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.101 · Cited by 87 · see citing works
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 87 · see citing works
Coffman, L. G., Burgos-Ojeda, D., WU, R. T., Cho, K. R., Bai, S., & Buckanovich, R. J. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.016 · Cited by 87 · see citing works
YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells
Hua, G., Lv, X., He, C., Remmenga, S. W., Rodabough, K. J., Dong, J., Yang, L., Lele, S. M., Yang, P., Zhou, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.288 · Cited by 83 · see citing works
Xie, Y., Park, E., Xiang, D., & Li, Z. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.08.021 · Cited by 81 · see citing works
TGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 76 · see citing works
Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer
Muñoz-Galván, S., & Carnero, A. (2020) · Cells · doi:10.3390/cells9061402 · Cited by 79 · see citing works
Dean, M., Davis, D. A., & Burdette, J. E. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.011 · Cited by 80 · see citing works
Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
George, S. H. L., Garcia, R., & Slomovitz, B. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00108 · Cited by 77 · see citing works
Xu, B., Lefringhouse, J., Liu, Z., Piecoro, D. W., Baldwin, L. A., Ou, C., Chen, L., Napier, D. L., Chaiswing, L., Brewer, L. D., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2016.86 · Cited by 76 · see citing works
The Ovary Is an Alternative Site of Origin for High-Grade Serous Ovarian Cancer in Mice
Kim, J., Coffey, D. M., Ma, L., & Matzuk, M. M. (2015) · Endocrinology · doi:10.1210/en.2014-1977 · Cited by 76 · see citing works
Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, L., Laury, A. R., Sareen, D., Barrett, R. J., Karlan, B. Y., & Svendsen, C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05519-2 · Cited by 74 · see citing works
Dissecting metastasis using preclinical models and methods
Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00568-4 · Cited by 75 · see citing works
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells
Yamamoto, Y., Ning, G., Howitt, B. E., Mehra, K. K., Wu, L., Wang, X., Yue, H., Kern, F., Wei, T. S., Zhang, T., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4649 · Cited by 75 · see citing works
WU, R. T., Zhai, Y., Kuick, R. D., Karnezis, A. N., Garcia, P. E., Naseem, A. F., Hu, T. C., Fearon, E. R., & Cho, K. R. (2016) · The Journal of Pathology · doi:10.1002/path.4783 · Cited by 75 · see citing works
Li, Y., Lu, S., Xu, Y., Qiu, C., Jin, C., Wang, Y., Liu, Z., & Kong, B. (2017) · PubMed Central · Cited by 74 · see citing works
Harrington, B. S., He, Y., Davies, C. M., Wallace, S. J., Adams, M. N., Beaven, E. A., Roche, D., Kennedy, C. J., Chetty, N., Crandon, A. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.471 · Cited by 73 · see citing works
Bartlett, T. E., Chindera, K., McDermott, J. R., Breeze, C. E., Cooke, W. R., Jones, A., Reisel, D., Karegodar, S. T., Arora, R., Beck, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11620 · Cited by 72 · see citing works
Dhaliwal, D., & Shepherd, T. G. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10136-5 · Cited by 71 · see citing works
Salpingectomy as a Means to Reduce Ovarian Cancer Risk
Daly, M. B., Drescher, C. W., Yates, M. S., Jeter, J., Karlan, B. Y., Alberts, D. S., & Lu, K. H. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0293 · Cited by 71 · see citing works
PAX8 and MECOM are interaction partners driving ovarian cancer
Bleu, M., Mermet‐Meillon, F., Apfel, V., Barys, L., Holzer, L., Salvy, M. B., Lopes, R., Barbosa, I. A. M., Delmas, C., Hinniger, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22708-w · Cited by 70 · see citing works
Roy, L., & Dahl, K. D. C. (2018) · Cancers · doi:10.3390/cancers10080241 · Cited by 69 · see citing works
PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation
Russo, A., Czarnecki, A. A., Dean, M., Modi, D., Lantvit, D. D., Hardy, L. R., Baligod, S., Davis, D. A., Wei, J., & Burdette, J. E. (2018) · Oncogene · doi:10.1038/s41388-017-0097-8 · Cited by 69 · see citing works
PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma
Bleu, M., Gaulis, S., Lopes, R., Sprouffske, K., Apfel, V., Holwerda, S. J. B., Pregnolato, M., Yildiz, U., Cordo’, V., Dost, A. F. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11672-1 · Cited by 68 · see citing works
Heath, O. M., Berlato, C., Maniati, E., Lakhani, A., Pegrum, C., Kotantaki, P., Elorbany, S., Böhm, S., Barry, S. T., Annibaldi, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0968 · Cited by 69 · see citing works
Ahmed, N., Kadife, E., Raza, A., Short, M. K., Jubinsky, P. T., & Kannourakis, G. (2020) · Cells · doi:10.3390/cells9030719 · Cited by 68 · see citing works
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
- Authors
- Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Dinulescu, Daniela M.
- Drapkin, Ronny
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 24
- Issue
- 6
- Pages
- 751-765
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3917315
- OpenAlex
- W2013107316
- Cited by
- 596
- References
- 58
- Citations by year
- 2026: 23 · 2025: 49 · 2024: 35 · 2023: 47 · 2022: 47 · 2021: 46 · 2020: 85 · 2019: 44 · 2018: 42 · 2017: 44 · 2016: 51 · 2015: 49 · 2014: 32
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health
- National Cancer Institute (R21CA156021, U01CA152990, P50CA105009)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- high-grade serous ovarian cancer, serous tubal intraepithelial carcinoma, cancer of unknown primary, BRCA1, BRCA2, TP53, PTEN, peritoneal cancer, precursor lesions, cancer prevention, early detection
- MeSH terms
- PAX8 Transcription Factor, Animals, Cell Transformation, Neoplastic, Epithelium, Fallopian Tube Neoplasms, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Precancerous Conditions, Genes, p53, Cystadenocarcinoma, Serous, Genes, BRCA1, Integrases, Genes, BRCA2, PTEN Phosphohydrolase, Mice, Paired Box Transcription Factors, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
